N/A N=14 Randomized Double-blind Treatment

PRP vs PRP Plus IGF for Patellar Tendinosis

Tendinopathy · Patellar Ligament · Platelet-Rich Plasma

Bottom Line

View on ClinicalTrials.gov: NCT04350827 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2023

Primary outcome: Primary: Victorian Institute of Sport Assessment-patellar Tendon (VISA-P) — 66.4; 78.2 units on a scale — p=0.433

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Platelet Rich Plasma (Device); Platelet Rich Plasma plus IGF (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ohio State University
Primary completion: Oct 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Victorian Institute of Sport Assessment-patellar Tendon (VISA-P)	66.4; 78.2	0.433
SECONDARY Visual Analog Scale-Pain	2.38; 1.30	—
SECONDARY Tegner Activity Scale	5.8; 6.5	—
SECONDARY Blazina Classification	4; 5; 0; 1; 1; 0	—

Summary

The purpose of this study is to compare two different platelet-rich plasma (PRP) injections for patellar tendinosis. Aim: To perform a randomized, double blinded study comparing the clinical effect of PRP versus PRP + concentrated insulin-like growth factor (IGF) in patients with patellar tendinosis.

Eligibility Criteria

Inclusion Criteria

>6 weeks of symptomatic patellar tendinosis
unilateral or bilateral
18 yrs of age or older
active in sport and exercise at least 3x / week
able to take time away from sport (for healing and rehabilitation phase after procedure)
failed at least 6 weeks of guided rehabilitation (under the supervision of either a certified athletic trainer or physical therapist)
minimum Tegner activity level of 4

Exclusion Criteria

Steroid injection in target knee in the last 3 months
PRP in the target knee in the last 6 months
No other cellular treatments in index knee (bone marrow, amniotic suspensions) last 1 year
Participation in any experimental device or drug study within 1 year before screening visit
Oral or IM steroids for last 3 months
Dry needling of patellar tendon in last 6 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04350827). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.